WOCKPHARMA - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.9
| Stock Code | WOCKPHARMA | Market Cap | 25,577 Cr. | Current Price | 1,575 ₹ | High / Low | 1,870 ₹ |
| Stock P/E | 87.6 | Book Value | 190 ₹ | Dividend Yield | 0.00 % | ROCE | 9.74 % |
| ROE | 9.99 % | Face Value | 5.00 ₹ | DMA 50 | 1,452 ₹ | DMA 200 | 1,397 ₹ |
| Chg in FII Hold | 0.09 % | Chg in DII Hold | 0.41 % | PAT Qtr | 132 Cr. | PAT Prev Qtr | 38.0 Cr. |
| RSI | 57.9 | MACD | 57.4 | Volume | 5,56,785 | Avg Vol 1Wk | 11,69,483 |
| Low price | 1,087 ₹ | High price | 1,870 ₹ | PEG Ratio | 1.81 | Debt to equity | 0.64 |
| 52w Index | 62.4 % | Qtr Profit Var | 230 % | EPS | 19.5 ₹ | Industry PE | 30.5 |
📊 Core Financials:
WOCKPHARMA has shown strong improvement with quarterly PAT rising from 38 Cr. to 132 Cr. (↑230%). ROCE at 9.74% and ROE at 9.99% are modest, reflecting average efficiency. Debt-to-equity is relatively high at 0.64, indicating leverage risk. EPS stands at 19.5 ₹, supported by recent profitability recovery, though margins remain thin.
💹 Valuation Indicators:
The stock trades at a P/E of 87.6, far above the industry average of 30.5, suggesting significant overvaluation. P/B ratio is ~8.29 (Price 1,575 ₹ / Book Value 190 ₹), which is elevated. PEG ratio of 1.81 indicates growth is priced at a premium. Intrinsic value appears lower than current levels, limiting margin of safety despite earnings recovery.
🏢 Business Model & Competitive Advantage:
WOCKPHARMA operates in pharmaceuticals with a diversified product portfolio and global presence. Its competitive advantage lies in scale, R&D capabilities, and established brand recognition. However, profitability metrics remain weaker than top peers, and debt levels reduce financial flexibility.
🎯 Entry Zone & Long-Term Guidance:
Current price (1,575 ₹) is above both 50 DMA (1,452 ₹) and 200 DMA (1,397 ₹), showing bullish momentum. RSI at 57.9 indicates moderate strength, while MACD (57.4) confirms strong positive momentum. A good entry zone would be 1,500–1,550 ₹ if undervaluation emerges. Long-term holding is possible due to sector demand, but stretched valuations and debt warrant caution.
Positive
- 📈 Quarterly PAT growth (↑230%).
- 💰 EPS improved to 19.5 ₹.
- 🌍 Institutional confidence with FII (+0.09%) and DII (+0.41%) increases.
- 📊 Strong technical momentum above DMA levels.
Limitation
- ⚠️ Very high P/E (87.6) vs industry average (30.5).
- 📉 Elevated P/B ratio (~8.29).
- 📉 Debt-to-equity relatively high (0.64).
- 📉 Dividend yield is 0.00%, no shareholder returns.
Company Negative News
📰 No major negative news reported recently, but high valuations and debt levels raise caution.
Company Positive News
📰 Quarterly earnings improved sharply with PAT rising to 132 Cr. Institutional holdings increased, reflecting investor confidence.
Industry
🏭 Industry P/E stands at 30.5, much lower than WOCKPHARMA’s valuation. The pharmaceutical sector remains resilient, driven by global healthcare demand, but competition and regulatory pressures persist.
Conclusion
✅ WOCKPHARMA is financially stable with strong earnings recovery and institutional support. However, valuations are stretched, and debt levels remain a concern. Best suited for cautious long-term investors who can accumulate near 1,500–1,550 ₹. Short-term traders may benefit from current bullish momentum but should monitor debt and valuation risks closely.
Would you like me to extend this into a pharma sector outlook to see how industry trends could impact WOCKPHARMA’s growth trajectory?